Business Description
Thiogenesis Therapeutics Corp
NAICS : 325412
SIC : 3741
ISIN : CA88410L1022
Description
Thiogenesis Therapeutics Corp is a clinical-stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company's compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live, and side effects and it's initial applications are for mitochondrial disease, Rett syndrome, and pediatric NASH.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.76 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -80.3 | |||||
| 3-Year EPS without NRI Growth Rate | -80.3 | |||||
| 3-Year FCF Growth Rate | -69.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.9 | |||||
| 9-Day RSI | 43.64 | |||||
| 14-Day RSI | 43.48 | |||||
| 6-1 Month Momentum % | -7.5 | |||||
| 12-1 Month Momentum % | -3.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.23 | |||||
| Quick Ratio | 4.23 | |||||
| Cash Ratio | 4.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -16.9 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -104.1 | |||||
| ROA % | -92.84 | |||||
| ROCE % | -104.1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 5.65 | |||||
| Price-to-Tangible-Book | 5.83 | |||||
| EV-to-EBIT | -5.63 | |||||
| EV-to-Forward-EBIT | -3.74 | |||||
| EV-to-EBITDA | -5.63 | |||||
| EV-to-Forward-EBITDA | -3.74 | |||||
| EV-to-FCF | -8.78 | |||||
| Price-to-Net-Current-Asset-Value | 5.83 | |||||
| Price-to-Net-Cash | 5.83 | |||||
| Earnings Yield (Greenblatt) % | -17.76 | |||||
| FCF Yield % | -10.2 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Thiogenesis Therapeutics Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | |||
| EPS (TTM) (C$) | -0.13 | ||
| Beta | 0 | ||
| Volatility % | 35.11 | ||
| 14-Day RSI | 43.48 | ||
| 14-Day ATR (C$) | 0.018797 | ||
| 20-Day SMA (C$) | 0.7125 | ||
| 12-1 Month Momentum % | -3.9 | ||
| 52-Week Range (C$) | 0.6 - 1.06 | ||
| Shares Outstanding (Mil) | 45.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Thiogenesis Therapeutics Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Thiogenesis Therapeutics Corp Stock Events
| Event | Date | Price(C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Thiogenesis Therapeutics Corp Frequently Asked Questions
What is Thiogenesis Therapeutics Corp(TSXV:TTI)'s stock price today?
The current price of TSXV:TTI is C$0.70. The 52 week high of TSXV:TTI is C$1.06 and 52 week low is C$0.60.
When is next earnings date of Thiogenesis Therapeutics Corp(TSXV:TTI)?
The next earnings date of Thiogenesis Therapeutics Corp(TSXV:TTI) is .
Does Thiogenesis Therapeutics Corp(TSXV:TTI) pay dividends? If so, how much?
Thiogenesis Therapeutics Corp(TSXV:TTI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers